By

phillipsandphillips
The Patient Voice Aotearoa team, with support from 35 patient advocacy groups, today published a full page ad in the Herald calling on the Prime Minister and her government to urgently fund medicines to save the lives of our most vulnerable, defenceless citizens during Covid-19. Myeloma New Zealand are proud to support the open letter, and...
Continue Reading
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG) presents the article of the week. The article from Australia’s National Centre for Infections in Cancer (NCIC, Peter MacCallum Cancer Centre) includes MSAG members Prof Jeff Szer and A/Prof Peter Mollee as co-authors.  Along with this guide for health care professionals please find attached the guide for patients, produced by...
Continue Reading
A Kiwi diagnosed with cancer has shared advice on how to self-isolate while living with others and what precautions immunocompromised people should take. The Government has announced that people travelling into New Zealand, except from the Pacific Islands, have to self-isolate for 14 days. This has sparked many questions on how self-isolation works and how...
Continue Reading
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined equally either by Multicolor Flow Cytometry (MFC) or by Next Generation Sequencing (NGS) technologies. At present, modern technologies allow to detect up to one on 104 or...
Continue Reading
Myeloma New Zealand is today calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid) from April this year, allowing eligible patients access the subsidised drug earlier in their course of treatment. As one of several groups that marched on Parliament in 2019 presenting petitions demanding an...
Continue Reading
Media Release In a move welcomed by patient advocacy group Myeloma New Zealand, drug buying agency Pharmac has proposed to widen access to blood cancer treatment lenalidomide (Revlimid).  Myeloma is an incurable type of blood cancer that starts in the bone marrow and leads to serious complications such as kidney failure, bone pain and infections....
Continue Reading
Highlights include: • Once-weekly vs twice weekly carfilzomib for newly diagnosed MM • Negative trials for pembrolizumab in treatment naive and relapsed/refractory MM • Daratumumab plus dexamethasone in triple refractory MM Download here: Multiple Myeloma Research Review Issue 32
Continue Reading
A summary of events and the status of medicines applications for myeloma currently with Pharmac   Tania Crosbie Special Projects Manager, Myeloma New Zealand   Despite advertising that Pharmac would be responding to the Health Select Committee (HSC) with regards to the myeloma petition at the Wednesday October 23rd HSC meeting, no oral feedback was...
Continue Reading
Go along in person or watch live on Facebook (see details below) as Pharmac presents their oral submission at the Committee’s meeting on Wednesday, 23 October 2019, from approximately 08.30am to 09.50am, at Parliament Buildings in Wellington. They will address all of the following petitions in one submission. Petition of Jeffrey Chan: Ask Pharmac to...
Continue Reading
Close relatives of people with blood cancer are more likely to be diagnosed with the disease themselves, a major study has found. An international team, led out of the Institute of Cancer Research in London, examined diagnosis, birth and death records of more than 150,000 people with all types of blood cancer — such as leukaemia, lymphoma or myeloma...
Continue Reading
1 2 3 4

Floor 7, 90 The Terrace
Wellington Central
New Zealand